

# AMGEN INC.

ISIN: US0311621009 WKN: 031162100 Asset Class: Stock

|                   |  |
|-------------------|--|
| <b>Company</b>    | 2022/01/25 17:51:00                            |
| <b>Price</b>      | <b>225.05</b>                                  |
|                   | USD  |
| <b>Difference</b> | <span style="color: red;">-0.46%(-1.03)</span> |



|                          |  |
|--------------------------|--|
| <b>Contact Details</b>   |  |
| AMGEN INC.               | Tel: 1-805-447-1000  |
| --                       | Fax: 1-805-447-1010  |
| One Amgen Center Drive   | Web: <a href="http://www.amgen.com">http://www.amgen.com</a> |
| 91320-1799 Thousand Oaks | E-mail: -  |

## Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2020           |                        | 2019           |                        | 2018           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 21,144,000,000 |                        | 18,440,000,000 |                        | 37,618,000,000 |                        |
| <b>Common stock capital</b>           |                | 31,802,000,000         |                | 31,531,000,000         |                | 31,246,000,000         |
| <b>Fixed assets</b>                   | 41,804,000,000 |                        | 41,267,000,000 |                        | 28,798,000,000 |                        |
| <b>Equity capital of a company</b>    |                | 9,409,000,000          |                | 9,673,000,000          |                | 12,500,000,000         |
| <b>Cash and cash equivalents</b>      | 6,266,000,000  |                        | 6,037,000,000  |                        | 6,945,000,000  |                        |
| <b>Accrued liabilities</b>            |                | 6,968,000,000          |                | 8,037,000,000          |                | 8,770,000,000          |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 11,653,000,000         |                | 12,835,000,000         |                | 13,488,000,000         |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 41,886,000,000         |                | 37,199,000,000         |                | 40,428,000,000         |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 1,717,000,000          |                | 1,218,000,000          |                | 1,284,000,000          |
| <b>Total assets</b>                   | 62,948,000,000 | 62,948,000,000         | 59,707,000,000 | 59,707,000,000         | 66,416,000,000 | 66,416,000,000         |

## Balance notes

|                            | 2020    | 2019    | 2018    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 24,300  | 23,400  | 21,500  |
| <b>Equity ratio</b>        | 14.95%  | 16.20%  | 18.82%  |
| <b>Debt-equity ratio</b>   | 569.02% | 517.25% | 431.33% |

## Others

|                         | 2020   | 2019   | 2018   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 10.68% | 14.18% | 12.06% |

# AMGEN INC.

ISIN: US0311621009

WKN: 031162100

Asset Class: Stock

## Income statement

|   | 2020           | 2019           | 2018           |
|---|----------------|----------------|----------------|
| Turnover  | 25,246,000,000 | 23,261,000,000 | 23,768,000,000 |
| Net income  | 7,264,000,000  | 7,842,000,000  | 8,394,000,000  |
| EBIT  | 8,415,753,600  | 8,674,944,000  | 8,543,585,600  |
| Operating income before taxes                                 | 8,133,000,000  | 9,138,000,000  | 9,545,000,000  |
| Cash Flow   | 10,497,000,000 | 9,150,000,000  | 11,296,000,000 |
| Net interest income   | -1,413,000,000 | -702,000,000   | -146,000,000   |
| Research and development expenses                             | 4,207,000,000  | 4,116,000,000  | 3,737,000,000  |
| Income taxes  | 869,000,000    | 1,296,000,000  | 1,151,000,000  |
| Result from investments in subsidiaries, associates and other | 0              | 0              | 0              |
| Revenues per employee   | 915,921        | 876,363        | 974,599        |

## Board of Directors

## Members of Management Board

|                     |                               |
|---------------------|-------------------------------|
| Brian Druker        | Member of Board of Directors  |
| Omar Ishrak         | Member of Board of Directors  |
| Robert Williams     | Member of Board of Directors  |
| Ronald Sugar        | Member of Board of Directors  |
| Tyler Jacks         | Member of Board of Directors  |
| Wanda Austin        | Member of Board of Directors  |
| Amy Miles           | Member of Board of Directors  |
| Charles Holley      | Member of Board of Directors  |
| Ellen Kullman       | Member of Board of Directors  |
| Greg Garland        | Member of Board of Directors  |
| Robert Eckert       | Member of Board of Directors  |
| Robert Bradway      | Chairman of Managing Board    |
| Annalisa Pizzarello | Member of Executive Committee |
| Anton Rabushka      | Member of Executive Committee |
| Arleen Paulino      | Member of Executive Committee |
| Darryl Sleep        | Member of Executive Committee |
| David A. Piacquad   | Member of Executive Committee |
| David M. Reese      | Member of Executive Committee |
| Esteban Santos      | Member of Executive Committee |
| Gilles Marrache     | Member of Executive Committee |
| Ian Thompson        | Member of Executive Committee |
| Jean-Charles Soria  | Member of Executive Committee |
| Jerry Murry         | Member of Executive Committee |
| Jonathan Graham     | Member of Executive Committee |
| Judy Gawlik Brown   | Member of Executive Committee |